Shares in Indivior (INDV) are up 36% year-to-date. The latest catalyst for the opioid-use disorder treatment specialist came in the form of 2023 sales and profit towards the top end of expectations and guidance for stronger than forecast profit growth in 2024 (22 February).

Also giving the shares a boost was the news the company plans to move its primary stock exchange listing to the US where it may achieve a higher valuation. The company listed its shares on Nasdaq in 2023.

At £17.63, the share are below the £20 mark they traded at in February 2023 when the firm took an unexpected $290 million provision to cover legacy litigation cases.

In October 2023, Indivior agreed to pay $385 million to settle certain some cases, resolving claims brought by direct purchasers that the firm suppressed competition for its opioid addiction treatment Suboxone.

Management expects 2024 net revenue to grow by 18% at the midpoint of the range ($1.29 billion) and to generate an adjusted operating profit of between $330 million and $380 million. 

‹ Previous2024-03-07Next ›